Mar 19, 2024
Labège, France, March 19th 2024. Antabio SAS, a clinical stage biopharmaceutical company developing novel treatments for severe drug-resistantbacterial infections, is pleased to announce the appointment of Dr. Erick Lelouche as Chairman of the Board of Directors....
Jan 2, 2020
The funding will be used to advance Antabio’s Pseudomonas Elastase Inhibitor (PEi) program up to completion of non-GLP preclinical studie Labège, France, 2nd January 2020. Antabio SAS, the biopharmaceutical company focused on developing a broad pipeline of...
Jun 4, 2019
Two presentations will focus on Antabio’s ANT2681, a novel Metallo β-Lactamase Inhibitor that restores the efficacy of Meropenem against clinical strains of NDM-producing CRE Antabio SAS, a private biopharmaceutical company developing novel antibacterial treatments...
Jan 22, 2019
We are pleased to announce that Antabio’s CEO Marc Lemonnier has been appointed as a new member of the Scientific Advisory Board (SAB) of JPIAMR. The Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) is a global collaborative platform, with 27 nations...
Mar 23, 2018
Antabio announces publication of a manuscript in Antimicrobial Agents and Chemotherapy: Discovery of a Novel Metallo-ß-Lactamase Inhibitor, which can Potentiate Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae Currently available as an ePublication :...
Jan 19, 2017
Antabio’s CEO Marc Lemonnier has been elected at the Board of Directors of the BEAM Alliance (Biopharmaceutical companies from Europe innovating in Anti-Microbial resistance research) further to the alliance’s Extraordinary General Assembly held in Paris on 20...
